volume 9, issue 9, P5139-5146 2020
DOI: 10.21037/tcr-20-988
View full text
|
|
Share

Abstract: Background: Interstitial pneumonia (IP) is a common and fatal adverse effect of rituximab-containing immunochemotherapy in lymphoma patients. Following prophylactic treatment with trimethoprimsulfamethoxazole (TMP-SMX), the clinical features, treatment, and risk factors for IP development remain largely undefined. Methods: From April 2015 and April 2018, 294 patients diagnosed with CD20+ B-cell non-Hodgkin lymphoma (NHL) were included in this study. All patients received front-line RCHOP-like chemotherapy and …

expand abstract